Antioxidant drug in neuroprotective therapy for glaucoma

Authors:
E.A. Egorov ¹ , A.A. Gvetadze ¹ , N.G. Davydova ²

¹ rnim them. N.I. Pirogov;
² FSBI "Moscow Research Institute of Eye Diseases. Helmholtz »Ministry of Health of the Russian Federation

Place of publication:
Bulletin of ophthalmology, No. 2, 2013

Summary:
The purpose of this study is to study the effectiveness and safety of the use of Mexidol as part of combined treatment of primary open -angle glaucoma (s). The study was involved in 94 patients (185) aged 18 to 75 years with the I -III staging, which were divided into 3 groups: 50 patients were prescribed combined treatment of 100 mg of Mexidol and 150 mg of picmilon, 22 patients took 300 mg of Mexidol and 150 MG picmilon, 22 patients received only 150 mg of picclon. Patients took drugs once a day for 14 or 21 days. The examination included standard ophthalmological, as well as perimetry, electroretinography, the study of the arterial blood flow of the retina and the optic disk. After taking combination therapy, an improvement in visual acuity, perimetry, electrophysiological parameters and increasing the velocity of arterial blood flow in the retina were recorded. Thus, combined therapy allows you to improve the treatment of patients with soup.